Cholesteryl Ester Transfer Protein – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)- Pipeline Review, H2 2019’, provides in depth analysis on Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Metabolic Disorders and Oncology under development targeting Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

– The report reviews Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics and enlists all their major and minor projects

– The report assesses Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Bristol-Myers Squibb Co

Chong Kun Dang Pharmaceutical Corp

DalCor Pharmaceuticals Inc

Pfizer Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Companies Involved in Therapeutics Development

Chong Kun Dang Pharmaceutical Corp

DalCor Pharmaceuticals Inc

Kowa Co Ltd

Pfizer Inc

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drug Profiles

CKD-508 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CKD-519 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalcetrapib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-16 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-312 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04445597 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CETP for Dyslipidemia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Dormant Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Discontinued Products

Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Product Development Milestones

Featured News & Press Releases

Apr 26, 2018: Discovery Explaining the Potential Cardiovascular Benefits of a Precision Therapy Based on the Genetic Profile

Apr 05, 2018: DalCor Announces Expansion and Accelerated Enrollment of the dal-GenE Clinical Trial

Aug 28, 2017: DalCor Achieves 50 percent Enrollment Milestone for Phase 3 Cardiovascular Trial

Mar 07, 2017: DalCor's Phase 3 Cardiovascular Trial, dal-GenE, Exceeds Targeted Enrollment Schedule

Nov 10, 2016: DalCor Announces Data to be Presented at the American Heart Association Scientific Sessions 2016 in New Orleans

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease

Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds

May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib

Sep 13, 2011: Study Shows Efficacy Of Imaging Technology In Evaluating Heart Disease Drug Dalcetrapib

Aug 29, 2011: Roche Announces Results From Two Exploratory Phase IIb Studies Of Dalcetrapib

Apr 01, 2011: Roche Announces Dalcetrapib Phase II Studies dal-VESSEL And dal-PLAQUE Show Encouraging Results

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Pipeline by DalCor Pharmaceuticals Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

Discontinued Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019 (Contd..2), H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports